Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.